Affimed N.V.: Modular ROCK™platform enabling multi-specific NK / T-cell bi-and tri-specific Abs. Aug 2018 deal with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics through application of ROCK platform. Lead NK cell engager AFM13 (CD30/CD16A) in Ph1b combo w/ Keytruda in Hodgkins and Ph2a (mono) in CD30(+) lymphoma including TCL. T-cell engager AFM11 (CD19/CD3) in 2 dose escalation studies in ALL and NHL.
Website:
Address:
Im Neuenheimer Feld 582
Heidelberg, 69120
Germany

Company Participants at Affimed KOL Event Dec 7

  • Adi Hoess, Ph.D., Chief Executive Officer
  • Florian Fischer, Ph.D., MBA, Chief Financial Officer
  • Gregory Gin, Head of Investor Relations

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.